Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Market Cap to Ebitda for ATE Citagenix

<< Previous

Bullboard Posts

Next >>

Comment by nozzpackon Aug 11, 2021 5:02am

123 Views

Post# 33683487

RE:RE:RE:Market Cap to Ebitda for ATE Citagenix

For the dental supply sector , the current valuation multiples are 4.4 times revenues and 15.2 times Ebitda.

These are hardly different than those which I referenced for the drug sales sector which Citagenix overlaps to some degree

https://www.brocair.com/pdfs/Dental%20Products%20Market%20Analysis%202019%20April.pdf

Personal opinions are useless for equity valuations.

Stop providing them..

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market